The use of high flow nasal cannula(HFNC) therapy as a noninvasive respiratory support approach for preterm infants is rapidly increasing.HFNC is an alternative to nasal continuous positive airway pressure(nCPAP) for treating apnea of prematurity, primary respiratory support for neonates with respiratory distress, post-extubation support, facilitating nCPAP weaning in preterm infants.In this article, the proposed mechanisms of HFNC and the evidence from clinical trials of HFNC use in preterm infants were reviewed, and recommendations for evidence-based practice were established. Key words: High flow; Nasal cannula; Infant, newborn
Read full abstract